Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Researchers identify CTLA-4 response marker
Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises €39m to provide POC for nangibotide
Latest NewsFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags €6.3m in Series A round
Latest NewsParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Latest NewsLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
Latest NewsLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
PDC*line Pharma welcomes Dr Channa Debruyne
AppointmentsPDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.
ADC Therapeutics set to go public
Latest NewsAntibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
iStar Medical SA raises €40.1m
Latest NewsGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
Avillion appoints Dr Anders Gersel Pedersen
AppointmentsAvillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
UniQure looking to raise US$200m
Latest NewsDutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq.